Skip to main content

Genetic polymorphisms of CYP2D6 oxidation in patients with systemic sclerosis

European Journal of Clinical Pharmacology volume 65, Article number: 971 (2009) Cite this article

Abstract

Background

Involvement of genetic and environmental factors in the pathogenesis of scleroderma has contributed to a number of studies whose aim is to elucidate the way in which xenobiotics exert effects on the occurrence of autoimmune processes resulting in development of systemic sclerosis (SSc).

Objective

The study dealt with the evaluation of the genetically determined polymorphism of CYP2D6, one of the phase I drug metabolizing isoenzymes, in patients suffering from SSc. Usefulness of the CYP2D6 genotype examination and prevalence of CYP2D6 gene mutation in light of susceptibility to SSc development were assessed.

Methods

Forty-three patients with SSc and 129 healthy volunteers were included in the study. Of the 43 patients with SSc, 17 fulfilled the criteria of diffuse SSc (dSSc) and 26 of limited SSc (lSSc). The determination of the CYP2D6 oxidative polymorphism was performed with the PCR-RFLP method.

Results

Relative risk of SSc development for particular genotype carriers expressed by the odds ratio (OR) was statistically significantly higher for subjects with CYP2D6*1/CYP2D6*4 (OR = 4.8; P < 0.001). A statistically significant correlation between the CYP2D6*4 allele prevalence and the risk for developing SSc was found (OR = 2.6; P = 0.0002).

Conclusion

Higher prevalence of the CYP2D6*4 mutated alleles in patients with SSc and the obtained OR values suggest that this mutation has the effect of increasing SSc morbidity rate.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Sabbagh N, Marez D, Queyrel V, Lo Guidice J-M, Spire C, Vanhille P, Jorgensen C, Hachulla E, Broly F (1998) Genetic analysis of cytochrome P450 CYP2D6 polymorphism in patients with systemic lupus erythematosus. Pharmacogenetics 8(3):191–194

    PubMed  Article  CAS  Google Scholar 

  2. Kortunay S, Bozkurt A, Bathum L, Basci NE, Calgüneri M, Brøsen K, Kayaalp SO (1999) CYP2D6 polymorphism in systemic lupus erythematosus patients. Eur J Clin Pharmacol 55(1):21–25

    PubMed  Article  CAS  Google Scholar 

  3. Zschieschang P, Hiepe F, Gromnica-Ihle E, Roots I, Cascorbi I (2002) Lack of association between arylamine N-acetyltransferase 2 (NAT2) and systemic lupus erythematosus. Pharmacogenetics 12(7):559–63

    PubMed  Article  CAS  Google Scholar 

  4. Skrętkowicz K, Skrętkowicz J, Gawrońska-Szklarz B, Górnik W, Rychlik-Sych M, Sysa-Jędrzejowska A (2005) Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis. Eur J Clin Pharmacol 60(11):773–778

    PubMed  Article  CAS  Google Scholar 

  5. Soejima M, Sugiura T, Kawaguchi Y, Kawamoto M, Katsumata Y, Takagi K, Nakajima A, Mitamura T, Mimori A, Hara M, Kamatani N (2007) Association of the diplotype configuration at the N-acetylotransferase 2 gene with adverse events with cotrimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 9(2):R23

    PubMed  Article  CAS  Google Scholar 

  6. Rychlik-Sych M, Skrętkowicz J, Gawrońska-szklarz B, Górnik W, Sysa-Jędrzejowska A, Skrętkowicz-Szarmach K (2006) Acetylation genotype and phenotype in patients with systemic lapus erythematosus. Pharmacol Rep 58(1):22–29

    PubMed  CAS  Google Scholar 

  7. Pawlik A, Ostanek L, Brzosko I, Dąbrowska-Zamojcin E, Gawrońska-Szklarz B (2004) The influence of N-acetyltransferase 2 polymorhism on rheumatoid arthritis activity. Clin Exp Rheumatol 22(1):99–102

    PubMed  CAS  Google Scholar 

  8. Beyeler C, Daly AK, Armstrong M, Astbury C, Bird HA, Idle JR (1994) Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity. J Rheumatol 21(6):1034–39

    PubMed  CAS  Google Scholar 

  9. Rychlik-Sych M, Skrętkowicz-Szarmach K, Gawrońska-Szklarz B, Górnik W, Skrętkowicz J (2006) Polimorfizm NAT2 w wybranych chorobach o podłożu autoimmunologicznym. Prob Ter Monit 17(4):239–244

    Google Scholar 

  10. May DG, Black CM, Olsen NJ, Csuka ME, Tanner SB, Bellino L, Porter JA, Wilkinson GR, Branch RA (1990) Scleroderma is associated with differences in individual routes of drug metabolism, a study with dapsone, debrisoquine, and mephenytoin. Clin Pharmacol Ther 48(3):286–95

    PubMed  Article  CAS  Google Scholar 

  11. von Schmiedeberg S, Fritsche E, Ronnau AC, Specker C, Golka K, Richter-Hintz D, Schuppe HC, Lehmann P, Ruzicka T, Esser C, Abel J, Gleichmann E (1999) Polymorphisms of the xenobiotic-metabolizing enzymes CYP1A1 and NAT-2 in systemic sclerosis and lupus erythematosus. Adv Exp Med Biol 455:147–152

    Google Scholar 

  12. Tan FK, Arnett FC (2000) Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 12:511–19

    PubMed  Article  CAS  Google Scholar 

  13. Stephens CO, Briggs DC, Whyte J, Artlett CM, Scherbakov AB, Olsen N, Gusseeva NG, McHugh NJ, Maddison PJ, Welsh KI (1994) Familial scleroderma - evidence for environmental versus genetic trigger. Br J Rheumatol 33(12):1131–35

    PubMed  Article  CAS  Google Scholar 

  14. Skrętkowicz J, Skrętkowicz-Szarmach K (2006) Uwarunkowania genetyczne w patogenezie twardziny układowej. Pol Merk Lek XX(115):117–120

    Google Scholar 

  15. Johnson RW, Tew MB, Arnett FC (2002) The genetics of systemic sclerosis. Curr Rheumatol Rep 4(2):99–107

    PubMed  Article  Google Scholar 

  16. Skrętkowicz J, Skrętkowicz-Szarmach K, Rychlik-Sych M (2004) Genetyczne uwarunkowania w patogenezie tocznia rumieniowatego układowego. Reumatologia 42(4):567–572

    Google Scholar 

  17. Englert H, Small-McMahon J, Chambers P, O’Connor H, Davis K, Manolios N, White R, Dracos G, Brooks P (1999) Familiar risk estimation on systemic sclerosis. Aust NZ J Med 29(1):36–41

    CAS  Google Scholar 

  18. Arnett FC, Cho M, Chatterjee S, Aquilar MB, Reveille JD, Mayes MD (2001) Familial occurrence frequencies and relative risk for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44(6):1359–62

    PubMed  Article  CAS  Google Scholar 

  19. De Keyser F, Peene I, Joos R, Naeyaert JM, Messiaen L, Veys EM (2000) Occurrence of scleroderma in monozygotic twins. J Rheumatol 27(9):2267–69

    PubMed  Google Scholar 

  20. Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DH, Arnett FC (2001) Association of fibrillin 1 single nucleotide polymorphism haplotypes with systemie sclerosis in Choctaw and Japanese populations. Arthritis Rheum 44(4):893–901

    PubMed  Article  CAS  Google Scholar 

  21. Wipff J, Giraud M, Sibilia J, Mouthon L, Meyer O, Tiev K, Airo P, Caramaschi P, Guiducci S, Garchon HJ, Matucci-Cerinic M, Kahan A, Avouac J, Boileau C, Allanore Y (2008) Polymorphic markers of the fibrillin-1 gene and systemic sclerosis in European Caucasian patients. J Rheumatol 35(4):643–49

    PubMed  CAS  Google Scholar 

  22. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K (2000) Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 165(11):6635–6639

    PubMed  CAS  Google Scholar 

  23. Tsuchiya N, Kuroki K, Fujimoto M, Murakami Y, Tedder TF, Tokunada K, Takehara K, Sato S (2004) Association of a functional CD19 polymorphism with susceptibility to systemie sclerosis. Arthritis Rheum 50(12):4002–7

    PubMed  Article  CAS  Google Scholar 

  24. Bartoli F, Angotti C, Fatini C, Conforti ML, Guiducci S, Blagojevic J, Melchiorre D, Fiori G, Generini S, Damjanov N, Rednic S, Pignone A, Castellani S, Abbate R, Matucci Cerinic M (2007) Angiotensin-converting enzyme I/D polymorphism and macrovascular disease in systemic sclerosis. Rheumatology 46(5):772–75

    PubMed  Article  CAS  Google Scholar 

  25. Mattuzzi S, Barbi S, Carletto A, Ravagnani V, Moore PS, Bambara LM, Scarpa A (2007) Association of polymorphism in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol 34(5):903–5

    Google Scholar 

  26. Beretta L, Cappiello F, Barili M, Scorza R (2007) Proximal interleukin-10 gene polymorphism in Italian patients with systemic sclerosis. Tissue Antigens 69(4):305–12

    PubMed  Article  CAS  Google Scholar 

  27. Arlett CM, Black CM, Briggs DC, Stevens CO, Welsh KI (1996) Telomere reduction in scleroderma patients, a possible cause of chromosomal instability. Br J Rheumatol 35(8):732–37

    Article  Google Scholar 

  28. Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC (1992) Debrisoquine hydroxylase gene polymorphism and suscebility to Parkinsons disease. Lancet 339(8806):1375–1377 6

    PubMed  Article  CAS  Google Scholar 

  29. Gołąb-Janowska M, Honczarenko K, Gawrońska-Szklarz B, Potemkowski A (2007) CYP2D6 gene polymorphism as a probable risk factor for Alzheimer’s disease and Parkinson’s disease with dementia. Neurol Neurochir Pol 41(2):113–121

    PubMed  Google Scholar 

  30. Ledesma MC, Aqundez JAG (2005) Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication. Clin Chem 51(6):939–943

    PubMed  Article  CAS  Google Scholar 

  31. Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, Mohan H (2006) CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA and Cell Biology 25(5):287–294

    PubMed  Article  CAS  Google Scholar 

  32. Sobti RC, Al-Badran AI, Sharma S, Sharma SK, Krishan A, Mohad H (2005) Genetic polymorphisms of CYP2D6, GSTM1, and GSTT1 genes and bladder cancer risk in North India. Cancer Genet Cytogenet 156(1):68–73

    PubMed  Article  CAS  Google Scholar 

  33. Perera FP, Deliang T, Brandt-Rauf P, Santella RM, Mooney VA, Tu Y-H, Bendkowska I, Bell DA (2006) Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in nested case-control study of lung cancer within the Physicians’ Health Study. Cancer Epidemiol Biomarkers Prev 15:1417–1419

    PubMed  Article  CAS  Google Scholar 

  34. Lapiński L, Agundez JAG, Wiela-Hojeńska A, Ganczarski G, Orzechowska-Józwenko K, Wołowiec D, Głowacka K, Kuliczkowski K (2007) CYP2D6 gene amplification and the risk of acute myeloblastic leukemia. Pharmacol Rep 59(1):167–172

    Google Scholar 

  35. Butler WJ, Ryan P, Roberts-Thomson IC (2001) Metabolic genotypes and risk for colorectal cancer. J Gastroenterol Hepatol 16(6):631–635

    PubMed  Article  CAS  Google Scholar 

  36. Woo S, Kim JW, Seo HG, Park CH, Han SH, Kim SH, Kim KW, Jhoo JH, Woo JI (2001) CYP2D6*4 polymorphism is not associated with Parkinson’s disease and has no protective role against Alzheimer’s disease in the Korean population. Psych Clin Neurosci 55(4):373–377

    Article  CAS  Google Scholar 

  37. Povey A, Guppy MJ, Wood M, Knight C, Black CM, Silman AJ (2001) Cytochrome P2 polymorphism and susceptibility to scleroderma following exposure to organic solvents. Arthritis Rheum 44(3):662–65

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grant No. 502-18-665 and No. 503-8011-1 from the Medical University of Lodz, Poland.

Author information

Affiliations

  1. Department of Pharmacogenetics, Medical University of Łódź, Muszyńskiego 1, 90-151, Lodz, Poland

    Jadwiga Skrętkowicz, Malgorzata Baranska & Mariola Rychlik-Sych

Authors
  1. Jadwiga Skrętkowicz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malgorzata Baranska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mariola Rychlik-Sych
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jadwiga Skrętkowicz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Skrętkowicz, J., Baranska, M. & Rychlik-Sych, M. Genetic polymorphisms of CYP2D6 oxidation in patients with systemic sclerosis. Eur J Clin Pharmacol 65, 971 (2009). https://doi.org/10.1007/s00228-009-0662-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00228-009-0662-3

Keywords

  • Genetic polymorphism
  • Oxidation
  • CYP2D6
  • Systemic sclerosis (SSc)